Focus on Pharmacotherapy for Irritable Bowel Syndrome with Constipation

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Irritable bowel syndrome with constipation (IBS-C) is a prevalent condition impacting patient quality of life.
• Effective therapeutic options are available for managing IBS-C symptoms.

Purpose of the Study:

• To review pivotal evidence for IBS-C therapeutics.
• To present recent treatment guidance from North American gastroenterological societies.

Main Methods:

• Review of clinical trial data for secretagogues (lubiprostone, linaclotide, plecanatide, tenapenor) and prokinetic agent tegaserod.
• Analysis of treatment guidelines from major North American gastroenterological societies.

Main Results:

• Secretagogues and tegaserod have demonstrated efficacy in improving IBS-C symptoms.
• Patient-specific treatment selection based on efficacy, safety, tolerability, access, and affordability is advised.

Conclusions:

• Multiple pharmaceutical classes effectively treat IBS-C.
• Personalized treatment strategies are crucial for managing IBS-C.